NCT06681870 2025-01-15A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid TumorsAstellas Pharma IncPhase 1 Withdrawn
NCT04985357 2024-11-25Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsTravera IncWithdrawn
NCT05238831 2024-01-23SMMART Adaptive Clinical Treatment (ACT) TrialOHSU Knight Cancer InstitutePhase EARLY_PHASE1 Withdrawn
NCT04602117 2023-11-18ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic CancerQuantumLeap Healthcare CollaborativePhase 1 Withdrawn
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn